CHESTNUT RIDGE, N.Y.,
Sept. 30, 2020 /PRNewswire/
-- BioHiTech Global, Inc. ("BioHiTech" or the "Company")
(NASDAQ: BHTG), a sustainable technology and services company,
announced today that the Company has shipped the first Altapure
AP-4™ high-level disinfectant system to the cruise
industry.
The Altapure AP-4 has been shipped to SeaDream Yacht
Club ("SeaDream") where it will be used as part of the safety
and disinfecting protocols for the SeaDream I yacht which is
scheduled to begin a season of Barbados round-trips in the fall of 2020.
Named "Best Small Luxury Cruise Ship of 2015" in ForbesLife,
twin mega-yachts SeaDream I & II are intimate boutique ships
that provide a unique travelling experience unlike any other cruise
vacation. The Altapure technology will be used in conjunction with
other sanitization equipment on a daily basis. SeaDream will also
conduct pre-boarding COVID testing and daily temperature checks to
best ensure passenger safety.
"The cruise industry faces unique challenges as each line seeks
to relaunch operations in this difficult new environment," said
Frank E. Celli, CEO of BioHiTech.
"SeaDream is now leading the way in health and safety through the
use of the Altapure AP-4 disinfection system. We have worked
diligently with their team to create protocols using the AP-4 for
regular disinfection of guest and crew cabins as well as dining
areas, health facilities and other commonly used areas. When
combined with other safety protocols, the Altapure AP-4 will help
SeaDream put passenger and crew safety first to create the safest
possible yachting experience. We look forward to helping SeaDream
and other like-minded cruise lines that are dedicated to achieving
the highest possible standards of disinfection for their customers
and employees."
The Altapure AP-4™ is an enhanced, automated
and touchless high-level disinfection sub-micron aerosol system
launched in 2017 that provides a safe process and rapid elimination
of spores, viruses, and vegetative bacteria, such as, but not
limited to: COVID-19, Acinetobacter baumanii, Pseudomonas
aeruginosa, VRE, MRSA, Bacillus atrophaeus, Geobacillus
stearothermophilus, Polio virus, C. auris and Clostridium difficile
(C. difficile). Extensive research and development
alongside Harris Corporation, formerly ITT Exelis, a top-tier
global aerospace, defense, and information solutions company,
resulted in the creation of a very unique and patented aerosol
generation technology that when coupled with the liquid
agent Altacare®, a reagent grade
peracetic acid solution, yields rapid and unparalleled results for
high level disinfection. Altapure is committed to providing its
customers with the highest quality products and processes in the
marketplace that are safe to use and are environmentally friendly.
All of Altapure's products are engineered, manufactured, and
assembled in the U.S.
About BioHiTech Global
BioHiTech Global, Inc. (NASDAQ:
BHTG), is a technology services company focused on providing
cost-effective solutions that improve environmental
outcomes. Our technologies for waste management include the
patented processing of municipal solid waste into a valuable
renewable fuel, biological disposal of food waste on-site, and
proprietary real-time data analytics tools to reduce food waste
generation. When used individually or in combination, our solutions
lower the carbon footprint associated with waste transportation and
can reduce or virtually eliminate landfill usage. In addition, we
distribute a patented technology that achieves high-level
disinfection of spaces such as classrooms, hotel or hospital rooms
and other enclosed areas to combat the spread of viruses and
bacteria without the use of harsh chemicals. Our unique
solutions enable businesses, educational institutions and
municipalities of all sizes to solve everyday problems in a smarter
and more cost-effective way while reducing their impact on the
environment. For more information, please
visit www.biohitech.com.
Forward Looking Statements
Statements in this press
release contain certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, as amended. Without
limiting the foregoing, words such as "anticipate," "believe,"
"continue," "could," "estimate," "expect," "explore," "evaluate,"
"intend," "may," "might," "plan," "potential," "predict,"
"project," "seek," "should," or "will," or the negative thereof or
other variations thereon or comparable terminology. These
forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond the
Company's control. These statements are also based on many
assumptions and estimates and are not guarantees of future
performance. These statements are estimates, based on information
available to management as of the date of this release, and are
subject to further changes. These statements may involve known and
unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of BioHiTech Global,
Inc. to be materially different from future results, performance or
achievements expressed or implied by such forward-looking
statements. BioHiTech Global, Inc. assumes no obligation to
publicly update or revise these forward-looking statements for any
reason, or to update the reasons actual results could differ
materially from those anticipated in these forward-looking
statements, even if new information becomes available in the future
in these forward-looking statements, even if new information
becomes available in the future. Our actual results may differ
materially from the results anticipated in these forward-looking
statements due to a variety of factors, including, without
limitation those set forth as "Risk Factors" in our filings with
the Securities and Exchange Commission ("SEC"). There may be other
factors not mentioned above or included in the BioHiTech's SEC
filings that may cause actual results to differ materially from
those projected in any forward-looking statement. BioHiTech Global,
Inc. assumes no obligation to update any forward-looking statements
as a result of new information, future events or developments,
except as required by securities laws.
Company Contact:
BioHiTech Global, Inc.
Richard Galterio
Executive Vice President
Direct: 845.367.0603
rgalterio@biohitech.com
www.biohitech.com
Investors:
ir@biohitech.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biohitech-provides-the-first-altapure-ap-4-disinfectant-system-to-the-cruise-industry-301141705.html
SOURCE BioHiTech Global, Inc.